Z-1245-2023 Class II Ongoing

Recalled by Maquet Cardiovascular, LLC — Wayne, NJ

FDA device recall Z-1245-2023 was initiated by Maquet Cardiovascular, LLC on Jan 30, 2023 and is designated Class II. Reason for recall: One (1) Fusion Bioline Vascular graft from lot 25162546, which failed guideline straightness testing, was intermingled with lot 25162549 and distributed to customers. Use of the affected graft may… The recall status is ongoing. Affected quantity: 1 (US).

Recall details

Product Type
Devices
Report Date
Mar 22, 2023
Initiation Date
Jan 30, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1 (US)

Product description

Fusion Bioline Vascular Graft, Part number M00201503046B0

Reason for recall

One (1) Fusion Bioline Vascular graft from lot 25162546, which failed guideline straightness testing, was intermingled with lot 25162549 and distributed to customers. Use of the affected graft may result in reduction of blood flow or unwanted tension causing bleeding and the formation of a pseudo-aneurysm.

Distribution pattern

US Nationwide distribution in the states of FL, IN, LA, MI, MO, NC, NV, NY, PA, TN, TX, VA, WA.

Code information

UDI-DI 00384409005942 Lot 25162546

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-1245-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-1245-2023. Report a data issue: hello@regdatalab.com.